Monoclonal antibody · Acts on transthyretin (TTR) · developed by Prothena Biosciences
PRX004 (also known as NN-6019) is an intravenously given agent studied in transthyretin (ATTR) amyloidosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03336580 | Phase 1 | Amyloidogenic Transthyretin (ATTR) Amyloidosis | Terminated | PRTA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Amyloidogenic Transthyretin (ATTR) Amyloidosis
Updated Oct 25, 2026. Something wrong or missing? Report it on the PRTA page.
See PRTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PRTA catalysts and pipeline →